New formulation approaches to improve solubility and drug release from fixed dose combinations: Case examples pioglitazone/glimepiride and ezetimibe/simvastatin

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 84, Issue 1, 2013, Pages 208-218

  Taupitz, Thomas ^a   Dressman, Jennifer B ^a   Klein, Sandra ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Dissolution enhancement; Fixed dose combination; Solid dispersions; Solubility improvement; Ternary comlexes

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; COPOLYMER; EZETIMIBE PLUS SIMVASTATIN; GLIMEPIRIDE PLUS PIOGLITAZONE; MACROGOL;

ARTICLE; DRUG RELEASE; DRUG SOLUBILITY; IN VITRO STUDY; PH; SOLID STATE; X RAY DIFFRACTION;

AZETIDINES; CHEMISTRY, PHARMACEUTICAL; DRUG COMBINATIONS; SIMVASTATIN; SOLUBILITY; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; X-RAY DIFFRACTION;

EID: 84876927688     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.11.027     Document Type: Article

References (43)

1. P. Gribbon, and A. Sewing High-throughput drug discovery: what can we exulect from HTS? Drug Discovery Today 10 1 2005 17 22
2. G.L. Amidon A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 3 1995 413 420
3. F. Nimmerfall, and J. Rosenthaler Dependence of area under the curve on proquazone particle-size and in vitro dissolution rate J. Pharm. Sci. 69 5 1980 605 607
4. K. Sigfridsson, A.J. Lundqvist, and M. Strimfors Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development Drug Dev. Ind. Pharm. 35 12 2009 1479 1486
5. B.C. Hancock, and G. Zograf Characteristics and significance of the amorphous state in pharmaceutical systems J. Pharm. Sci. 86 1 1997 1 12
6. A.A. Noyes, and W.R. Whitney The rate of solution of solid substances in their own solutions J. Am. Chem. Soc. 19 1897 930 934
7. N. Nernst Theory on the reaction rate in heterogenous systems Phys. Chem-Stoch 47 1904 52 55
8. T. Loftsson, and M.E. Brewster Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization J. Pharm. Sci. 85 10 1996 1017 1025
9. M.E. Davis, and M.E. Brewster Cyclodextrin-based pharmaceutics: past, present and future Nat. Rev. Drug Discovery 3 12 2004 1023 1035
10. T. Loftsson, M. Masson, and M.E. Brewster Self-association of cyclodextrins and cyclodextrin complexes J. Pharm. Sci. 93 5 2004 1091 1099
11. R.A. Rajewski, and V.J. Stella Pharmaceutical applications of cyclodextrins.2. In vivo drug delivery J. Pharm. Sci. 85 11 1996 1142 1169
12. T. Loftsson Self-assembly of cyclodextrin complexes: aggregation of hydrocortisone/cyclodextrin complexes Int. J. Pharm. 407 1-2 2011 174 183
13. A.H. Goldberg, M. Gibaldi, and J.L. Kanig Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures. 2. Experimental evaluation of a eutectic mixture-urea-acetaminophen system J. Pharm. Sci. 55 5 1966 482 484
14. C. Leuner, and J. Dressman Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharm. Biopharm. 50 1 2000 47 60
15. T. Ohara Dissolution mechanism of poorly water-soluble drug from extended release solid dispersion system with ethylcellulose and hydroxypropylmethylcellulose Int. J. Pharm. 302 1-2 2005 95 102
16. T. Kimura Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): in vivo evaluation J. Control. Rel. 112 1 2006 51 56
17. G. Ktistis Effect of hydrogen bonding interactions on the release mechanism of felodipine from nanodispersions with polyvinylpyrrolidone Eur. J. Pharm. Biopharm. 63 2 2006 103 114
18. A. Paradkar Development, characterization and stabilization of amorphous form of a low T-g drug Powder Technol. 167 1 2006 20 25
19. G.R. Lloyd, D.Q.M. Craig, and A. Smith A calorimetric investigation into the interaction between paracetamol and polyethlene glycol 4000 in physical mixes and solid dispersions Eur. J. Pharm. Biopharm. 48 1 1999 59 65
20. T. Loftsson The effect of water-soluble polymers on drug-cyclodextrin complexation Int. J. Pharm. 110 2 1994 169 177
21. T. Loftsson Increasing the cyclodextrin complexation of drugs and drug bioavailability through addition of water-soluble polymers Pharmazie 53 11 1998 733 740
22. A. Frick, H. Moller, and E. Wirbitzki Biopharmaceutical characterization of oral immediate release drug products. In vitro in vivo comparison of phenoxymethylpenicillin potassium, glimepiride and levofloxacin Eur. J. Pharm. Biopharm. 46 3 1998 305 311
23. L.Z. Benet Predicting drug disposition via application of a biopharmaceutics drug disposition classification system Basic Clin. Pharmacol. Toxicol. 106 3 2010 162 167
24. T. Rohban The efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during Ramadan Diabetes Care 28 2 2005 421 422
25. T.A. Jones Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes Diabetes Obes. Metab. 5 3 2003 163 170
26. N. Seedher, and M. Kanojia Co-solvent solubilization of some poorly-soluble antidiabetic drugs Pharm. Dev. Technol. 14 2 2009 185 192
27. H.Y. Cheng Evaluation of sustained controlled-release dosage forms of 3-hydroxy-3-methylglutaryl coenzyme a (Hmg-Coa) reductase inhibitors in dogs and humans Pharm. Res. 10 11 1993 1683 1687
28. A. Paradkar, A.A. Ambike, and K.R. Mahadik Spray-dried amorphous solid dispersions of simvastatin, a low T-g drug: in vitro and in vivo evaluations Pharm. Res. 22 6 2005 990 998
29. S.H. Cho Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs Int. J. Pharm. 274 1-2 2004 65 73
30. L. Oner, T. Gulsun, and R.N. Gursoy Design and characterization of nanocrystal formulations containing ezetimibe Chem. Pharm. Bull. 59 1 2011 41 45
31. M. Vertzoni Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects J. Pharm. Pharmacol. 56 4 2004 453 462
32. A. Glomme, J. Marz, and J.B. Dressman Comparison of a miniaturized shake-flask solubility method with automated potentiometric acid/base titrations and calculated solubilities J. Pharm. Sci. 94 1 2005 1 16
33. USP, USP 34/NF 29, I. United States Pharmacopeia Convention. 2011, Rockville MD: United States Pharmacopeia Convention, Inc.
34. PhEur, European Pharmacopoeia, seventh ed., vol. 7, Council of Europe, 2011.
35. S. Klein The mini paddle apparatus-a useful tool in the early developmental stage? Experiences with immediate-release dosage forms Dissol. Technol. 13 4 2006 6 11
36. S. Klein, and V. Shah A standardized mini paddle apparatus as an alternative to the standard paddle AAPS. PharmSiTech. 9 4 2008 1179 1184
37. T. Kosoglou Ezetimibe-a review of its metabolism, pharmacokinetics and drug interactions Clin. Pharmacokinet. 44 5 2005 467 494
38. M. Valero, B.I. Perez-Revuelta, and L.J. Rodriguez Effect of PVPK-25 on the formation of the naproxen: beta-ciclodextrin complex Int. J. Pharm. 253 1-2 2003 97 110
39. H.O. Ammar Implication of inclusion complexation of glimepiride in cyclodextrin-polymer systems on its dissolution, stability and therapeutic efficacy Int. J. Pharmaceut. 320 1-2 2006 53 57
40. P. Augustijns, J. Brouwers, and M.E. Brewster Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J. Pharm. Sci. 98 8 2009 2549 2572
41. T. Zoeller, J.B. Dressman, and S. Klein Application of a ternary HP-beta-CD-complex approach to improve the dissolution performance of a poorly soluble weak acid under biorelevant conditions Int. J. Pharm. 430 1-2 2012 176 183
42. E. Jantratid Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update Pharm. Res. 25 7 2008 1663 1676
43. J.B. Dressman Evaluation of various dissolution media for predicting in vivo performance of classes I and II drugs Pharm. Res. 15 5 1998 698 705